Search Results
Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
Search for other papers by Eilon Krashin in
Google Scholar
PubMed
School of Public Health, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
Search for other papers by Barbara Silverman in
Google Scholar
PubMed
Search for other papers by David M Steinberg in
Google Scholar
PubMed
Search for other papers by Daniel Yekutieli in
Google Scholar
PubMed
Search for other papers by Shmuel Giveon in
Google Scholar
PubMed
Search for other papers by Offer Fabian in
Google Scholar
PubMed
Search for other papers by Aleck Hercbergs in
Google Scholar
PubMed
Search for other papers by Paul J Davis in
Google Scholar
PubMed
Hematology Institute and Blood Bank, Meir Medical Center, Kfar-Saba, Israel
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
Search for other papers by Martin Ellis in
Google Scholar
PubMed
Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
Search for other papers by Osnat Ashur-Fabian in
Google Scholar
PubMed
Research on the association between thyroid hormone levels and cancer mortality remains limited and inconclusive. We determined the relation of thyroid stimulating hormone (TSH), free T4 (FT4), and free T3 (FT3) levels with mortality in overall cancer and specific tumor types. Thyroid hormone levels 1–5 years prior to cancer diagnosis, as well as multiple clinical and demographic parameters, were retrospectively collected for 10,325 Israeli cancer patients, diagnosed between 2000 and 2016. Patients treated with thyroid altering medications were excluded. Cancer diagnosis was determined via the Israel National Cancer Registry. Multivariate-adjusted Cox proportional hazards model was used to assess the hazard ratios (HRs) based on thyroid hormone function for cancer mortality. A total of 5265 patients died during the follow-up period (median of 4.4 years). TSH, FT4, and FT3 levels in the hypothyroid range were associated with increase in overall mortality (adjusted HR 1.20, 1.74, 1.87, respectively). We further analyzed the association between TSH and mortality in 14 cancer subgroups. Specifically, TSH in both the hyperthyroid and hypothyroid range was associated with melanoma mortality (adjusted HR 2.20, 4.47, respectively). In conclusion, pre-diagnosis of thyroid dysfunction is associated with increased cancer mortality, a relation likely driven by specific cancer types. These findings suggest that thyroid hormones may potentially serve as prognostic markers in cancer.